Ultragenyx Pharmaceutical Intangible Assets

As of the most recent data (June 2026), RARE shows a intangible assets of $170M. That compares with $170M in the prior-year period — down 1.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RARE's intangible assets is now $170M (was $170M) — a 1.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ultragenyx Pharmaceutical is outperforming or lagging.

Tracking RARE's intangible assets over time shows whether Ultragenyx Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $170M That compares with $170M in the prior-year period — down 1.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Ultragenyx Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $170M) with ownership activity and broader fundamentals.

Ultragenyx Pharmaceutical's intangible assets is $170M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.